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1015-9584/Copyright ª 2015, Asian SuSummary Background: A pulmonary tumor is occasionally detected on a chest computed to-
mography (CT) scan before cardiovascular surgery.
Purpose: In this study, we examined clinical courses of patients who had undergone the simul-
taneous resection of a pulmonary tumor following cardiovascular surgery.
Methods: From 2008 to 2013, 18 patients (13 men and 5 women) with a median age of 69.8
years underwent the wedge pulmonary resection for a lung tumor through a median thoracot-
omy following cardiovascular surgery in our hospital. Cardiovascular surgeries consisted of off-
pump coronary artery bypass grafting (CABG) in six patients, aortic valve replacement and/or
mitral valve plasty in 10 patients, total arch replacement in 10 patients and descending aorta
replacement in 10 patients.
Results: No complications associated with pulmonary resections were observed. Pathological
examination revealed that 15 patients (83.3%) were diagnosed with lung cancers including
13 adenocarcinomas and two squamous cell carcinomas, with the clinical stages of 1A in 13 pa-
tients, 2A in one patient and 2B in one patient. Among them, five patients received the radical
pulmonary resection subsequently, whereas 10 patients were unable to receive it due to their
poor cardiopulmonary function. Kaplan-Meier analysis of patients with lung cancer revealed
that the 5-year survival rate and progression-free survival (PFS) rate after 3 years from the sur-
gery were 46.2% and 73.8%, respectively.
Conclusion: The simultaneous resection of pulmonary tumor following cardiovascular surgery
is safely performed, and is useful for the pathological diagnosis of the tumor. Further studieseclare that they have no financial conflicts of interests to disclosed.
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Age (median)
Gender
Male (%)
Female (%)
Cardiovascular surgery
OPCAB (%)
AVR and/or MVP (%)
AVR and TAR (%)
TAR (%)
DAR (%)
Location of pulmonary tumor
Right lung (%)
Upper
Middle
Lower
Left lung (%)
Upper
Lower
AVR Z aortic valve replacement;
replacement; MVP Z mitral valve p
coronary artery bypass grafting; TAR
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cancer in patients with cardiovascular disease with comorbidities.
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reserved.1. Introduction
Lung cancer is the leading cause of cancer-related death in
males in the Asia-Pacific region and globally,1,2 and it
accounted for 13% (1.6 million) of the total cancer cases
and 18% (1.4 million) of deaths in 2008.1 In Japan, the total
number of general thoracic surgeries in 2012 was 72,899,
and > 49% of those cases underwent surgery for lung can-
cer.3 The number of patients diagnosed with lung cancer is
steadily increasing, leading to an increase in the number of
patients undergoing thoracic surgery. Furthermore, the
number of cardiovascular surgeries for adults was reported
to be > 50,000 in Japan in 2012.3 An unhealthy lifestyle
seems to be a major factor for the increase in thoracic and
cardiovascular surgeries, and the number of these surgeries
continues to increase.
Cases of concomitant lung cancer with cardiovascular
disease are also increasing. Cases of incidental pulmonary
tumor, which is detected by chest computed tomography
(CT) before cardiovascular surgery is performed, present
the greatest challenge for surgeons. Johnson and col-
leagues reviewed 3364 consecutive patients who had un-
dergone coronary artery bypass grafting (CABG) and
reported that 191 patients (5.7%) had pulmonary nodules.4
As opposed to cases of pulmonary nodules with calcifica-
tion, for pulmonary nodules suspected to be lung cancer ins.
50w86 (69.8)
13 (72)
5 (28)
6 (33)
9 (50)
1 (5.6)
1 (5.6)
1 (5.6)
11 (61)
7
2
2
7 (39)
2
5
DAR Z descending aorta
lasty; OPCAB Z off-pump
Z total arch replacement.
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.doi.org/10.1016/j.asjsur.2015.04patients with cardiovascular disease, guidelines for the
diagnosis and treatment of pulmonary nodules are yet to be
established.
To obtain the diagnosis for an incidental pulmonary
tumor detected before cardiovascular surgery, patients
undergo conventional radiological and serological exami-
nations, which are in part useful for the diagnosis. How-
ever, physicians appear reluctant to perform examinations
to obtain the pathological diagnosis of the tumor before
cardiovascular surgery because of the poor cardiovascular
function of the patients. Thus, some physicians may
consider performing a bronchoscopy after cardiovascular
surgery; however, there is an increased risk of bleeding
following a transbronchial lung biopsy (TBLB) due to the
administration of anticoagulant drugs after cardiovascular
surgery.5
To resolve such a dilemma, we performed simultaneous
resection of pulmonary tumor during cardiovascular sur-
gery. In previous papers on this surgical procedure, patients
who had undergone a radical surgery, such as a lobectomy
or a pneumonectomy, for lung cancer and cardiovascular
surgery simultaneously were included.6e9 The pulmonary
vascular bed is decreased by a lobectomy or a pneumo-
nectomy, causing a serious strain on cardiac function. Thus,
although it has been reported that this surgical procedure is
safe, postoperative complications may increase because of
the radical lung surgery.
With this in mind, during cardiovascular surgery, we
decided to perform simultaneous wedge resection of inci-
dental pulmonary tumor which had been detected prior to
cardiovascular surgery. We previously reported early to
mid-term results of this procedure, demonstrating that
there was neither operative mortality nor any major car-
diac complication associated with it and that it had a mean
progression-free survival (PFS) time of 17 months.10
In the present report that included more patients than
the previous report, the safety and effectiveness of this
procedure were evaluated retrospectively. We herein
report that this procedure can be safely performed and is
useful to obtain the pathological diagnosis of incidental
pulmonary tumors. In addition, this procedure may be
useful for controlling the progression of lung cancer in pa-
tients with severe cardiovascular disease.2. Patients and methods2.1. Patients
From February 2008 to April 2013, incidental pulmonary
tumors were detected using preoperative chest CT in 18
patients who had been scheduled for cardiovascular surgeryction of pulmonary tumor following cardiovascular surgery, Asian
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and the patients consisted of 13 men and five women, none
of whom reported any symptoms associated with the pul-
monary tumor. Cardiovascular surgeries that had been
planned were as follows: off-pump CABG in six patients,
aortic valve replacement and/or mitral valve plasty in nine
patients, aortic valve replacement and total arch replace-
ment in one patient, total arch replacement in one patient,
and descending aorta replacement in one patient. The
preoperative CT scan revealed that pulmonary tumors were
located in the right lung in 11 patients (upper, 7; middle, 2;
lower, 2) and in the left lung in seven patients (upper, 2;
lower, 5). In all cases, through the findings of preoperative
chest CT, the pulmonary tumors were suspected to be lung
cancers, with neither hilar adenopathy nor mediastinal
masses observed. Common preoperative examinations for
cardiovascular surgery, such as brain CT and pulmonary
function tests were performed. To obtain the pathological
diagnosis of the pulmonary tumor, cytological examination
of the sputum was performed, and neither TBLB nor CT-
guided needle biopsy were preoperatively planned.
2.2. Surgical procedure
Informed consent to perform simultaneous resection of the
pulmonary tumor was obtained from all patients prior to
surgery. During surgery, a double lumen endotracheal tube
was introduced in the patient. A median sternotomy was
performed in 17 patients and a left posterolateral thora-
cotomy in one patient. After completion of cardiovascular
surgery and administration of protamine, wedge resection
of the pulmonary tumor was performed using an automatic
suture instrument via median sternotomy or left postero-
lateral thoracotomy; consequently, an additional incision
was not required for the pulmonary resection. Hilar and
mediastinal lymph nodes were not sampled.
2.3. Statistical analysis
The overall survival (OS) and PFS after simultaneous pul-
monary resection were estimated by the Kaplan-Meier
method. A log-rank test was used to compare these sur-
vival times in different groups of patients.
3. Results
3.1. Operative mortality and surgical complications
No operative mortalities or hospital deaths were observed
in patients who had undergone simultaneous resection of
the pulmonary tumor during cardiovascular surgery.
Regarding surgical complications, we were mostly con-
cerned about thoracic hemorrhage due to wedge resection
of the pulmonary tumor; however, this did not occur in any
patient, and therefore, no patients required a re-
thoracotomy. We were also concerned about an increased
risk of air leakage and pneumonia after the simultaneous
pulmonary resection; however, this did not occur in any
patient. In addition, other cardiovascular surgical compli-
cations, such as perioperative or postoperative myocardialPlease cite this article in press as: Kaku R, et al., Simultaneous rese
Journal of Surgery (2015), http://dx.doi.org/10.1016/j.asjsur.2015.04infarction, cardiac tamponade, and stroke, were not
increased by the simultaneous pulmonary resection.3.2. Pathological diagnoses of pulmonary tumors
Among the 18 patients, three patients were diagnosed with
benign tumors, including granuloma (1 patient), inflam-
matory tumor (1 patient), and teratoma (1 patient) (Table
2). The other 15 patients were pathologically diagnosed
with non-small cell lung cancer (NSCLC), consisting of nine
adenocarcinomas, four bronchioloalveolar cell carcinomas,
and two squamous cell carcinomas. Pathological findings
also demonstrated that malignant tumor cells were not
observed in the resected lung margins in any patient. The
clinical stages of NSCLC cases were determined to be 1A in
13 patients, 2A in one patient, and 2B in 1 patient.3.3. Staged radical surgery for NSCLC
Of the 15 patients with NSCLC, five underwent staged
radical surgery for NSCLC 1e14 months after the initial
simultaneous pulmonary resection (Table 2). The patho-
logical stages of them were determined to be 1A in three
patients, 2A in one patient, and 2B in one patient. Among
them, three patients underwent a lobectomy and two un-
derwent a segmentectomy. Their pulmonary function
became worse after cardiovascular surgery; however, we
considered that this was acceptable given the benefits of
the radical pulmonary resection. The remaining 10 patients
were considered not suitable for additional pulmonary
surgery due to low cardiopulmonary function, poor perfor-
mance status, or severe comorbidities.3.4. Postoperative clinical courses of patients with
NSCLC
The median follow-up period of patients with NSCLC was 19
months, ranging from 2 to 60 months. Two patients died
from NSCLC, and others died from other medical issues
including cardiac insufficiency, colon cancer, and unknown
reasons. Local recurrences were observed in three patients
5e12 months after the initial simultaneous pulmonary
resection. Kaplan-Meier analysis in all patients with NSCLC
revealed that the median OS was 45 months (Fig. 1A), and
the median PFS was not reached (Fig. 1B). The PFS at 3
years after the initial simultaneous pulmonary resection
was 73.8%, and the 5-year survival rate was 46.2%. In pa-
tients who underwent staged radical surgery for NSCLC, the
median OS after the initial simultaneous pulmonary resec-
tion was 45 months, which tended to be shorter than that of
patients who did not undergo the radical surgery (median
OS is not reached, p Z 0.3678) (Fig. 2A). The median PFS
also tended to be shorter in patients who had undergone
the staged radical surgery than in those who had not (11
months vs. not reached, pZ 0.2914) (Fig. 2B). The PFS at 3
years and the 5-year survival rate after the initial simul-
taneous pulmonary resection was not improved by the
staged radical surgery for NSCLC (30.0% vs. 58.3%,
p Z 0.3678; 40.0% vs. 87.5%, p Z 0.2914, respectively).ction of pulmonary tumor following cardiovascular surgery, Asian
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Table 2 Summary of patients with lung cancer.
Case Sex Age
(y)
Cardiovascular
surgery
Tumor
location
Clinical
stage
Radical
surgery
Pathology Prognosis
(time from initial surgery)
1 M 73 OPCAB þ Y-graft Rt. upper IA  BAC Alive (60 mo)
2 M 54 TAR Lt. lower IA Lob þ ND1b Adeno Alive (59 mo)
3 M 77 AVR þ MVP þ maze Rt. lower IA  SqCC Alive (53 mo)
4 M 70 OPCAB Rt. lower IIA Lob þ ND1b SqCC Dead from AMI (45 mo)
5 M 86 OPCAB Rt. upper IA  Adeno Follow-up loss (30 mo)
6 F 78 AVR Lt. lower IA  Adeno Follow-up loss (2 mo)
7 M 50 OPCAB Lt. lower IA Seg þ ND1b BAC Dead from colon cancer (8 mo)
8 M 78 MVP þ Bentall þ maze Lt. lower IA  Adeno Dead from lung cancer (9 mo)
9 M 83 DAR Rt. upper IA  Adeno Dead from unknown disease (33 mo)
10 M 77 AVR Rt. upper IA  Adeno Alive (28 mo)
11 M 67 OPCAB Lt. upper IIB Lob þ ND1b Adeno Dead from IP (12 mo)
12 F 75 AVR þ TAR Rt. middle IA  Adeno Alive (14 mo)
13 F 60 AVR þ CABG Lt. lower IA Seg þ ND1b BAC Alive (19 mo)
14 M 63 OPCAB þ PVI Rt. upper IA  Adeno Alive (19 mo)
15 F 78 MVP Rt. upper IA  BAC Follow-up loss (6 mo)
AAR Z ascending aorta replacement; Adeno Z adenocarcinoma; AVR Z aortic valve replacement; BAC Z bronchioloalveolar cell
carcinoma; CABG Z coronary artery bypass grafting; DAR Z descending aorta replacement; Lob Z lobectomy; IP Z interstitial
pneumonitis; MVP Z mitral valve plasty; ND Z nodal resection; OPCAB Z off-pump coronary artery bypass grafting; PVI Z pulmonary
vein isolation; Seg Z segmentectomy; SqCC Z squamous cell carcinoma; TAR Z total arch replacement.
4 R. Kaku et al.
+ MODEL4. Discussion
In this study, we evaluated the safety and efficacy of
simultaneous resection of the pulmonary tumor during
cardiovascular surgery, demonstrating that this procedure
was safe and useful for the pathological diagnosis of the
tumor and may control the progression of lung cancer in
patients with a high risk of severe cardiovascular disease.
The incidence of perioperative rebleeding is more
frequent in cardiovascular surgeries than other types of
surgery due to the administration of anticoagulants. Thus,
we suspected that simultaneous resection of the pulmo-
nary tumor during cardiovascular surgery might increase
the risk of perioperative thoracic hemorrhage. However,
our study revealed that this was not the case. Previous
papers have reported that this is quite a rare complication
of simultaneous pulmonary resection during cardiovascu-
lar surgery,6,8,11e13 demonstrating that simultaneous pul-
monary resection does not significantly enhance the risk
of perioperative thoracic hemorrhage in cardiovascular
surgery. In all cases of the present study, the resection of
pulmonary tumor was performed after completion of
cardiovascular surgery. The surgical procedure for the
pulmonary tumor in all cases was the wedge resection, the
less complicated surgical technique. Thus, the resection
of pulmonary tumor could have been performed before
cardiovascular surgery in the present study. However,
pulmonary resection before cardiovascular surgery might
cause intrapulmonary hemorrhage, leading to respiratory
dysfunction during cardiovascular surgery. Thus, the
resection of pulmonary tumor was performed after
completion of cardiovascular surgery. Recently, there
have been improvements in automatic suture instruments
for pulmonary resection, and this has contributed to a
lower incidence of perioperative thoracic hemorrhage
despite administration of anticoagulants.Please cite this article in press as: Kaku R, et al., Simultaneous rese
Journal of Surgery (2015), http://dx.doi.org/10.1016/j.asjsur.2015.04In patients with an incidental pulmonary tumor, TBLB by
flexible bronchoscopy is performed for pathological diag-
nosis. In some cases, TBLB is useful to obtain the patho-
logical diagnosis of pulmonary tumors. However, as seen in
the present study, physicians may be reluctant to perform a
bronchoscopy before cardiovascular surgery because of the
unstable cardiac function. If TBLB is performed after the
surgery, the risk of hemorrhage may increase due to the
administration of anticoagulants. In addition, bronchoscopy
seems to be less suitable for pathological diagnosis
compared with the finding of grand glass opacity detected
on chest CT. On the basis of these results, we conclude that
simultaneous resection of pulmonary tumor can be safely
performed during cardiovascular surgery.
It may be possible to perform a single-stage complete
resection for lung cancer, such as pneumonectomy, lobec-
tomy, or segmentectomy during cardiovascular surgery via
a thoracotomy. In our study, all patients underwent wedge
resection for their pulmonary tumors during cardiovascular
surgery. Several months later, curative complete resection
for lung cancer was only performed on 33.3% of patients
who were evaluated to be capable of enduring additional
lung surgery. The other patients who did not undergo sub-
sequent complete pulmonary resection had low cardiopul-
monary function, poor performance status, and severe
comorbidities. Previous papers have reported that simul-
taneous complete resection for lung cancer during cardio-
vascular surgery was associated with high perioperative
mortality rates.3 Given that high-risk patients were
included in these studies, single-stage complete resection
for lung cancer during cardiovascular surgery may not have
been suitable.
In patients with resectable NSCLC, the recommended
surgical procedure should still be a lobectomy or a greater
pulmonary resection, with hilar and mediastinal lymph
nodes dissection.14,15 Concerning lymph nodes dissection,ction of pulmonary tumor following cardiovascular surgery, Asian
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Figure 1 (A) Kaplan-Meier analysis on overall survival time of
patients with lung cancer; (B) Kaplan-Meier analysis on
disease-free survival time of patients with lung cancer.
A
B
Figure 2 (A) Kaplan-Meier analysis on overall survival time of
patients with lung cancer by radical pulmonary surgery; (B)
Kaplan-Meier analysis on disease-free survival time of patients
with lung cancer by radical pulmonary surgery.
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mediastinal lymph nodes sampling, mediastinal lymph
nodes dissection did not improve the chance of survival in
patients in the early stages of NSCLC, suggesting that
dissection or sampling of mediastinal lymph nodes would
provide significant value to the staging of lung cancer. In
the present study, we assessed whether subsequent com-
plete pulmonary resection after simultaneous wedge
resection of pulmonary tumor during cardiovascular surgery
would improve the prognosis in patients in the early stages
of NSCLC. Unfortunately, the prognosis tended to be rela-
tively worse than that in patients who had not undergone
the additional pulmonary resection. Although our study
included a limited and small cohort of patients, we could
still conclude that complete pulmonary resection did not
seem to contribute to the improved prognoses in patients
with severe cardiovascular diseases. We speculated on the
reasons for the association between additional pulmonary
resection and a poorer prognosis. The patients who un-
derwent simultaneous resection of pulmonary tumor during
cardiovascular surgery may have had less residual cardio-
pulmonary function, which impeded the physiological re-
covery from the additional lung surgery. In addition, thosePlease cite this article in press as: Kaku R, et al., Simultaneous rese
Journal of Surgery (2015), http://dx.doi.org/10.1016/j.asjsur.2015.04patients had multiple comorbidities such as diabetes, renal
failure, and hyperglycemia.
The number of patients in whom an incidental pulmo-
nary tumor is detected before cardiovascular surgery will
increase in the future with the advancements in chest CT
scanning; however, the standard surgical strategy for pa-
tients with such tumors remains unclear. Johnson and col-
leagues4 reviewed 3364 consecutive patients undergoing
CABG and reported that 191 patients (5.7%) had pulmonary
nodules. Among those 191 patients, 40 patients had non-
calcified pulmonary nodules requiring follow-up. In that
study, 18 patients with noncalcified pulmonary nodules
underwent simultaneous resection of pulmonary nodules
during CABG, and 11 patients (61.1%) were diagnosed with
lung cancer. Similar to our report, 15 of 18 patients (83.3%)
were diagnosed with lung cancer, demonstrating that pa-
tients with lung cancer were frequently those who under-
went the concomitant surgery. These findings indicate that
careful interpretation of chest CT is necessary to avoid the
resection of benign tumors that can be left untreated.
Concerning the prognosis of patients who underwent
simultaneous resection of lung cancer, Zhang and col-
leagues7 reported that the 5-year survival rate for thesection of pulmonary tumor following cardiovascular surgery, Asian
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wedge resection for lung cancer, and four of them subse-
quently underwent lobectomy staged as IB or IIA. In our
report, which included patients with relatively early stages
of lung cancer, the 5-year survival rate was 46.2%, consis-
tent with the previous report. In contrast, Dyszkiewicz and
colleagues8 reported a 5-year survival rate of 0% in patients
who had undergone simultaneous resection of Stage II and
III lung cancers, suggesting that the pathological stage of
lung cancer is likely to be associated with the prognosis of
patients, as well as in the case of simultaneous pulmonary
resection.
In conclusion, simultaneous resection of pulmonary
tumor following cardiovascular surgery can be performed
safely and is useful for pathological diagnosis. In patients
with severe multiple comorbidities, this procedure pos-
sesses some possibility to control the progression of lung
cancer.
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